Cancer Innovation
Suffolk and North East Essex

Caroline Angus

March 2021

2WW Referral pathway
Innovation: Clinical Decision Support Tool

- C the signs - Clinical Decision Support Tool implemented across all practices in IES CCG.

- Launching April 2021

- GPs can access the tool (integrated with Systm1 or EMIS) during the consultation, it supports with recommendations, considerations and resources, as well as the referral process.

- The practice dashboard provides support for patient safety-netting.

- Evaluation in partnership with Eastern AHSN (Academic Health Science Network)

Teledermatology
Innovation: AI skin cancer triage

- Skin Analytics DERM solution, a clinically validated AI service that can identify 11 lesion types including:
  - Melanoma
  - Non-Melanoma skin cancers
  - Precancerous lesions which can be treated with prescription medicines
  - Benign lesions
- Development of pathway integrated with the Rapid Diagnostic Service
- Funding agreed Mar 21

Lung health checks
Innovation: Early CDT lung

- Early CDT-Lung is a simple blood test that has been developed to measure a panel of seven autoantibodies to tumour associated antigens related to lung cancer.

- Pilot a targeted screening programme for identified high risk individuals using a combination of a blood test followed by CT imaging, in those with a positive blood test.

- Launching NEE April 2021

Identification of Barrett's oesophagus Innovation: Cytosponge

- The Cytosponge®-TFF3 test has been developed as a non-endoscopic diagnostic modality for oesophageal disease which involves a device called the Cytosponge™ combined with laboratory assessment of the morphology and immune-histochemical biomarkers.

- Pilot Cytosponge as a diagnostic test available via a mobile diagnostic unit in primary care to support earlier and increased identification of pre-cancerous Barrett's oesophagus.

- Pilot in partnership with Heartburn Cancer UK in East Suffolk PCN, launch September 2021

Secondary Care Innovations

- Colon Capsule Endoscopy ESNEFT part of national trial and WSFT developing service

- Cytosponge in secondary care WSFT part of national pilot and DELTA trial

- EarlyCDT-Lung can be used in the risk classification of people with IPNs found by chest CT or X-ray.

Innovations: Horizon Scanning

- Innovation Survey – [click here](#)

- The [PinPoint](#) Test is a clinical decision support tool that produces a calibrated probability of cancer for a patient on a given 2WW referral pathway. It combines signals from a range of blood measurements (using a machine learning algorithm).

- The [Vinehealth](#) app allows people living with cancer to track their symptoms, manage their medications and understand their care.

- [Airglove](#) meets the need for oncology vascular access and can benefit fragile, hidden or damaged veins by gently vasodilating them with timed thermal regulation in 3 minutes.